Gapping up
In reaction to earnings/guidance:
- URBN +17.5%, CRM +14.7%, PLAN +13.4%, DKS +11.5%, INTU +7%, HPE +6.8%, TOL +2.4%, DY +2.3%, RY +1.3%, CHS +0.8%
Other news:
- FLDM +22.1% (receives Emergency Use Authorization from the FDA for saliva-based Advanta Dx SARS-CoV-2 RT-PCR assay for COVID-19)
- BKU +10.7% (to join S&P SmallCap 600)
- TRUP +9.2% (to join S&P SmallCap 600)
- WDAY +2.9% (in sympathy with strong earnings report from CRM)
- OII +2.6% (announces contract with Dynetics)
- VNET +2.2% (prices follow-on offering of 17 mln ADSs at $20.75 per ADS)
- TRVN +1.9% (announced two publications of the respiratory safety data from the OLINVYK development program)
- BRO +1.7% (terminates previously-announced agreement to acquire the assets of HAUSER)
- RDFN +1.1% (publishes positive industry report on website)
- IMVT +0.9% (LGND says partner IMVT announced positive top-line results for Phase 2a trial of IMVT-1401)
Analyst comments:
- NIO +6.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- ROKU +3.4% (initiated with a Buy at Citigroup)
- NBLX +2.4% (upgraded to Overweight from Neutral at Piper Sandler)
- HAIN +1.8% (upgraded to Outperform from In-line at Evercore ISI)
- KDP +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- POR +1.6% (upgraded to Buy from Hold at Siebert Williams Shank)